

Expected Values

Serum/Plasma

The following NCEP cutpoints for patient classification are used for the prevention and management of coronary heart disease :

| | |
|------------|--------------------------------------|
| Desirable | < 130 mg/dl (< 3.36 mmol/l) |
| Borderline | 130 - 159 mg/dl (3.36 - 4.11 mmol/l) |
| High Risk | ≥ 160 mg/dl (4.14 mmol/l) |

Note:

Expected range varies from population to population. It is therefore recommended that each laboratory should establish its own normal range.

Performance Characteristics

Linearity

With AutoPure T LDL-C, the assay is linear upto 450 mg/dl (11.637 mmol/l). Determine samples with higher concentrations via the rerun function. On analyzers without rerun function, manually dilute sample with higher concentrations using 0.9% NaCl or distilled / deionized water (e.g. 1 + 4). Multiply the result by the appropriate dilution factor (e.g. 5).

Interference

There is no significant interference in samples containing upto 20 mg/dl of conjugated & unconjugated bilirubin, 1293 mg/dl of triglycerides, 500 mg/dl of haemoglobin, 50 mg/dl ascorbic acid & 5000 mg/dl gamma globulins.

Precision

Reproducibility was determined using three levels of pooled human sera as shown below :

| Serum Pool | n=20 | | | n=40 | | |
|---------------------|------------|----------|------|------------|----------|------|
| | Mean mg/dl | SD mg/dl | %CV | Mean mg/dl | SD mg/dl | %CV |
| Low (<130 mg/dl) | 98.1 | 0.72 | 0.73 | 98.1 | 2.2 | 2.27 |
| Mid (130-159 mg/dl) | 146.5 | 0.96 | 0.66 | 142.7 | 2.8 | 1.95 |
| High (>160 mg/dl) | 209.8 | 1.31 | 0.62 | 207.3 | 3.6 | 1.73 |

Co-Relation Studies

A comparison of LDL-C determination using AutoPure T LDL-C and the Reference method gave the following co-relation (mg/dl) :

Linear regression

$$y = 0.95x + 3.02$$





$$r = 0.96$$

No. of samples measured : 54

References

1. **Centers for Disease Control/National Institutes of Health Manual** "Biosafety in Microbiological and Biomedical Laboratories", 1988.
2. National Committee for Clinical Laboratory Standards, Preparation and Testing of Reagent Water in the Clinical Laboratory Third edition: **Approved Guideline NCCLS Document C3-A3**, 1997.
3. Gotto, A.M. Lipoprotein Metabolism and the Etiology of Hyperlipidemia. **Hospital Practice** 1988; 23 Suppl:1 4-13.
4. Crouse, J.R. et al. Studies of Low Density Lipoprotein molecular weight in human beings with coronary artery disease. **J. Lipid Res** 1985; 26:566.
5. Badimon, J.J. et al. Regression of Artherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the cholesterol-Fed Rabbit. **J. Clin. Invest.** 1990; 85:1234.
6. Castelli, W.P. et al. HDL Cholesterol and other lipids in Coronary Heart Disease, **Circulation** 1977; 55:767.
7. Barr; D.P. et al. Protein-Lipid Relationships in Human Plasma. **Am. J. Med.** 1951; 11:480.
8. Gordon, T. et al. High Density Lipoprotein as a Protective Factor Against Coronary Heart Disease. **Am. J. Med.** 1977; 62:707.

9. Bachorik, P.S. et al. National Cholesterol Education Program Recommendations for Measurement of Low Density Lipoprotein Cholesterol: Executive Summary. **Clin. Chem.** 1995; 41(10):1414.
10. National Committee for Clinical Laboratory Standards, Internal Quality Control Testing: Principles and Definitions, **Approved Guideline NCCLS Document C24-A**, Number 6, Vol. 11, 1991.
11. National Committee for Clinical Laboratory Standards, Procedures for the Handling and Processing of Blood Specimens, **Approved Guideline NCCLS Document H18-A**, Number 12, Vol. 10, 1990.
12. Tietz, N.W. **Clinical Guide to Laboratory Tests**, W.B. Saunders Co., Philadelphia, PA., 256(1986).
13. National Committee for Clinical Laboratory Standards, **National Evaluation Protocols for Interference Testing, Evaluation Protocol**, Proposed Guideline NCCLS Document EP7-P Number 7, Vol. 6, No. 13, August 1986.
14. Young, D.S. Effects of Drugs on Clinical Laboratory Tests, 3rd ed. **AACC Press**, Washington, D.C., 3-104 (1990).

| | | | |
|-----|------------------------------|---|------------------------|
| IVD | In Vitro Diagnostic Use |  | Date of Manufacturing |
| i | Consult Instructions for use |  | Use by (YYYY-MM-DD) |
| REF | Catalogue Number |  | Temperature Limitation |
| LOT | Batch Code |  | Manufacturer |



AR. No.: I 34

ALL-2009-05-001



Accurex Biomedical Pvt. Ltd.

Head Office - Mumbai. Tel.: 91 (022) 67446744; Fax: 91 (022) 67446755

E-mail: accurex@vsnl.com; Website: www.accurex.org

Plant : G-54, MIDC Tarapur, Boisar, Thane - 401 506. INDIA.

TLDL-C™

Third Generation
Direct Homogeneous Assay

ACCUREX

AutPure

